T he etiologic importance of sodium chloride (salt) in the genesis or maintenance of hypertension remains controversial. Salt is, however, an independent predictor of left ventricular hypertrophy (LVH), 1 which raises the intriguing possibility that salt can damage target organs independently of its effects on blood pressure (BP). In general, confusion about the role of salt may well have arisen for 2 reasons. First, only certain subpopulations of hypertensive patients may be harmed by excess salt. Second, to this point most studies have examined whether salt alters BP per se rather than whether salt adversely affects the target organs independently of any effect on BP. In the present study we examined the effect of salt on QT dispersion and on left ventricular (LV) diastolic function in patients with relative aldosterone excess. QT dispersion is thought to be an index that represents the degree of inhomogeneity of cardiac electric repolarization. QT dispersion Ͼ80 ms has been reported to be a potent prognostic marker of sudden cardiac death in hypertension. 2 The diagnostic test of salt loading with the addition of low-dose fludrocortisone is used in hypertensive subjects who have a raised aldosterone/renin ratio (ARR) to look for evidence of autonomous aldosterone production, as occurs in primary aldosteronism. Patients undergoing this routine procedure provided us with a susceptible group in whom to test our hypothesis that salt could worsen QT dispersion and LV diastolic relaxation. Patients with raised ARR have inappropriate aldosterone activity, 3 and animal studies 4 suggest an important interaction between excess salt and excess aldosterone in producing target-organ damage in the heart.
Methods

Subject Selection
All hypertensive patients referred to our center had blood samples taken for plasma renin activity (PRA, ng/mL per hour) and aldosterone (pmol/L) after the patients had been sitting for 10 minutes. The ARR was used to identify potential patients with primary aldosteronism. 5 Those patients with an elevated ratio (Ն750) were hospitalized as part of a routine clinical workup over a 4-day period for the salt loading and fludrocortisone suppression test, the protocol of which has previously been described. 5 Briefly, this involved 28.8 g (480 mmol) of sodium chloride and 1.5 mg of fludrocortisone in divided doses over the period of hospitalization. All subjects were also given 2 tablets of Slow-K (600 mg/8.06 mmol of potassium chloride each) daily to maintain normokalemia. Plasma and not urinary sodium, together with other electrolytes, was measured at baseline and at the end of the study period. Patients were on ad libitum dietary sodium intake, averaging 3.5 g/d throughout the study while in the hospital. Body weight, supine BP measured with an automatic sphygmomanometer (NPB 4000, Nellcor Puritan Bennett), and ECG with simultaneous 12-lead acquisition at a paper speed of 25 mm/s (Hewlett Packard 4700A electrograph) were recorded before and after treatment, as was an echocardiographic examination performed to assess LV structure and systolic and diastolic function. Nonsuppression of plasma aldosterone (ie, Ն140 pmol/L at 1200 hours, upright and ambulant and/or at 0800 hours, supine) at the end of the test period was deemed diagnostic for primary aldosteronism. 6 The salt loading and fludrocortisone suppression test, ECG recording, and echocardiographic examination formed part of our routine hypertension assessment in our center. Therefore, formal ethical approval for this observational study was not required from the Tayside Medical Ethics Committee other than informed consent, which was obtained from each study subject.
QT Dispersion Measurement
A single observer (C.A.J.F.), blinded to the order of ECG recording and other measurements, analyzed all the ECGs. The methodology used in measuring the QT intervals (QT dispersion [QT and QTc dispersion] and QTc max ), which has an intraobserver coefficient of variation of Ͻ10%, has been described elsewhere. 7 
Echocardiographic Examination
All echocardiographic examinations were conducted by a single operator (P.S.) using a Hewlett Packard Sonos 2500. All echocardiographic parameters were measured in triplicate and averaged over 3 cardiac cycles. The following indexes of LV dimensions were recorded/derived from M-mode measurements obtained at the level of the papillary muscles in the short-axis view: LV internal diameter in diastole (LVIDD), LV internal diameter in systole (LVIDS), fractional shortening (FS), and LV mass index (LVMI). 8 waves and E/A ratio) and isovolumic relaxation time (IVRT) were obtained as previously described. 9 The color M-mode flow propagation velocity (CMMFPV) was measured according to the method described by Brun and colleagues. 10 
Laboratory Testing
The radioimmunoassay techniques used to measure PRA and plasma aldosterone have been described elsewhere. 3, 11 
Statistical Analysis
Descriptive statistics were expressed as mean (SD). Pretreatment and posttreatment changes in the QT indexes (QT dispersion, QTc dispersion, and QTc max ) were analyzed with paired t tests. Linear regressional analyzes were used to assess relationships between baseline QT indexes with correlated factors such as BP and plasma electrolytes and neurohormones. The effects of age and gender on QT indexes were also assessed, although these factors have not been shown in previous studies to affect QT indexes. Model and distributional assumptions inherent in the regressional analyzes were assessed. The Pearson correlation coefficients between baseline and changes in QT indexes, baseline and changes in plasma aldosterone (supine and ambulant), electrolytes, and echocardiographic indexes were calculated. All statistical tests were 2-tailed, and probability values Յ0.05 were considered significant. The statistical software package MINITAB 13.1 was used for these analyses.
Results
For a period of 21 months from May 1995, a total of 465 hypertensive subjects had ARR measured. Seventy-seven subjects (16.6%) had an elevated ratio of Ն750, as previously reported. 5 Of these, 29 subjects (14 men) aged 56 (SD 11) years consented to participate in this study when they were hospitalized for the salt loading and fludrocortisone suppression test. The ECG recordings were of good quality, and therefore the mean number of leads measurable was 11.6 (SD 0.6). There were no significant changes in body weight, supine pulse rate, or BP with salt and fludrocortisone ( Table  1) . Twenty-four of 29 study subjects (82.8%) failed to suppress their plasma aldosterone Ͻ140 pmol/L with salt and fludrocortisone. None of these subjects had an adrenal adenoma or glucocorticoid suppressible hyperaldosteronism.
QT Dispersion
At baseline only 1 subject had a QT dispersion Ͼ80 ms, but after administration of salt and fludrocortisone 12 subjects (41.4%) crossed this threshold for high risk of sudden cardiac death ( Figure) . However, when the 5 subjects with suppressible aldosterone were excluded, this value rose to 50%. The QT indexes in the 5 subjects with suppressible aldosterone were also increased, achieving statistical significance for QTc dispersion ( Table 2) . 
Plasma Electrolytes
After administration of salt and fludrocortisone, the plasma sodium concentration increased slightly but significantly, and the plasma potassium concentration dropped slightly despite oral supplementation (Table 1) . However, the baseline values of these electrolytes did not correlate with the QT indexes, and there were no significant relationships between the changes in these electrolytes and those of the QT indexes. Plasma urea and creatinine were both reduced with salt and fludrocortisone, but the pretreatment and posttreatment ratios of urea to creatinine were not significantly different (Pϭ0.626) ( Table 1) .
Echocardiography
Fifteen (9 men, aged 57 [SD 11] years) of the 29 subjects had complete research-quality echocardiograms both before and after treatment. The QT indexes in this subgroup were similarly increased with salt and fludrocortisone (QT dispersion, ϩ22. , and 73.3% of subjects had echocardiographic LVH. The FS, LA size, LVIDS, and LVIDD were all within normal limits at baseline (Table 3) . These indexes were unchanged after administration of salt and fludrocortisone in contrast to salt loading with intravenous sodium chloride infusion. 12 Weight, pulse rate, and BP were not changed in this subgroup of subjects. However, most of the LV diastolic filling indexes were significantly impaired by salt and fludrocortisone (Table 3) , indicating worsening LV diastolic function. Thus, worsening LV diastolic function occurred at the same time as increasing QT dispersion. 
Discussion
Our cohort of hypertensive subjects with raised ARR had raised QT dispersion at baseline (55 [SD 17.8] ms). This is consistent with other studies of hypertensive patients, which found the following mean QT indexes: QT dispersion, 50 to 64 ms; QTc dispersion, 67 ms; and QTc max , 435 to 464 ms. 13 Population studies of healthy subjects suggest that a "normal" QT dispersion should be Ͻ50 ms, independent of age or gender. 13 In approximately a third of our participants, QT dispersion was Ͼ80 ms after administration of salt and fludrocortisone, an at-risk level for sudden cardiac death. We have previously reported that approximately 15% of the hypertensive population in our clinic 5 have a raised ARR. In theory, this subpopulation of hypertensive subjects may be more at risk if exposed to excess salt, although evidence to this effect is lacking at present. We have not studied subjects without a raised ARR, but, interestingly, the small subset of subjects who suppressed their aldosterone also had increased QT dispersion (QT and QTc dispersion) with salt and fludrocortisone, albeit to a lesser degree. It is therefore possible that QT dispersion changes are not confined to this subgroup of hypertensive subjects, but this should be studied separately in the future. Our data show that both systolic BP and ambulant plasma aldosterone were independent predictors of QTc dispersion, as has been shown before. LVH 7, 14 and systolic BP 7, 15 at baseline have also been reported to correlate positively with QT dispersion, but our study did not find these relationships. One possible reason is that our study subjects were highly selected, and there might not have been enough variation within this subgroup to uncover these relationships. For example, only approximately a quarter of our subjects had normal LV mass.
The key findings in our study were that salt with fludrocortisone increased both QT dispersion and LV diastolic dysfunction. Several possible mediators of this effect can be excluded. Since the study was of short duration, the mechanism for the increased QT dispersion and the diastolic dysfunction is unlikely to be due to increased cardiac fibrosis or LVH. Additionally, since both supine and ambulant plasma aldosterone levels dropped significantly in response to salt and fludrocortisone, it is unlikely that aldosterone directly caused these effects on its own. Our echocardiographic data excluded any significant changes in LV systolic function or LV dimensions; therefore, increased chamber sizes do not explain our findings, nor do the changes in LV systolic function. 16 The most likely mediator of salt/fludrocortisone-induced changes in QT dispersion is salt-induced changes in LV stiffness and diastolic dysfunction (the role of fludrocortisone will be discussed below).
There is a wealth of previous work that would explain why salt should lead to myocardial stiffness, which would lead in turn to increased QT dispersion. The hypothesis of Blaustein et al 17 states that high extracellular sodium ionic concentration translates into increased intracellular ionic calcium concentration. The plasma sodium concentration rose by a small but significant amount in our study subjects after administration of salt with fludrocortisone, in keeping with this hypothesis. These cytosolic calcium ions increase muscular contractility but impair relaxation. 17 This chain of events could lead to a state of increased systemic vascular resistance when the vascular smooth muscle cells are involved and to impaired LV diastolic function when the cardiac myocytes are affected. This might explain our echocardiographic findings. Since salt with fludrocortisone impaired diastolic LV function without altering diastolic BP in this study, this suggests that the myocardium may be even more sensitive to salt-induced stiffness than the peripheral vasculature. Furthermore, it is not surprising that QT dispersion as a measure of LV electric repolarization should reflect LV diastolic relaxation, consistent with the well-known electromechanical feedback phenomenon. The probable link between salt and LV diastolic function that we have found may potentially explain why LV diastolic dysfunction occurs in hypertensives without frank LVH and even in subjects with borderline (or white coat) hypertension. 18 Indeed, Schlaich and colleagues 19 recently reported that high sodium intake in young hypertensives in comparison to normotensives is associated with less plasma aldosterone suppression and with a deterioration of LV diastolic function, which is consistent with one of our major findings.
Our study had no placebo control, but QT interval measurements were measured blindly, and these have been shown to have good long-term reproducibility, even between observers. 20 QT dispersion as a derived index has been used successfully in long-term trials to assess drug effects in hypertensive subjects. As in our present study, a single observer analyzed all the ECGs in these trials. 14, 15, 20, 21 Additionally, the QT dispersion was increased in our study rather than reduced in response to an intervention, making "regression to the mean" an unlikely explanation for our findings. 14, 15 The consistency between increasing QT dispersion and worsening echocardiographic-derived LV diastolic indexes was further evidence for the validity of our data, especially since both measurements were made by different "blinded" individuals. The CMMFPV in particular has been invasively validated, 10 and it is one of the most reliable noninvasive diastolic indexes and thought to be unaffected by preload, 22 which might be increased with salt and fludrocortisone. In addition, the echocardiographic E/A ratio was significantly reduced and IVRT was prolonged, suggesting worsening LV diastolic function. These changes were the opposite of those that would be expected by increasing preload. However, interpretation of these latter echocardiographic indexes could be confounded by "pseudonormalization," although the CMMFPV data made this unlikely to be an issue in the present study. The fludrocortisone used in this study had an impact on our findings. The dose used (0.5 mg/d) has a mineralocorticoid effect equipotent with aldosterone. 23 However, fludrocortisone has sympatholytic activity, 24 and this would tend to reduce QT dispersion 15 and improve LV diastolic function. 25 Thus, if fludrocortisone had any direct influence on our results, these would be expected to be the opposite of those observed. Instead, the use of fludrocortisone allowed us to demonstrate the adverse effects of salt in a shorter time frame (and with a lesser amount) than otherwise would be needed because fludrocortisone amplified salt retention via its mineralocorticoid activity. In any case, the majority of study subjects had nonsuppressible aldosterone, and the effect of this native mineralocorticoid was likely to have persisted throughout the study.
One possible confounder was the reduction in plasma potassium observed after administration of salt and fludrocortisone. In heart failure, QTc dispersion is nonsignificantly reduced with potassium infusion (Pϭ0.08), 26 but a reverse relationship has not been demonstrated. However, if we assume that such a relationship existed and that it was applicable to hypertensive subjects, each mean 0.1-mmol/L fall in plasma potassium might be associated with a 6.7-ms mean increase in QTc dispersion. The change in plasma potassium observed in our study might therefore account for an increase in QTc dispersion of 13.3 ms (a mean plasma potassium reduction of 0.2 mmol/L after salt/fludrocortisone). The observed rise in QTc dispersion was much greater, being nearly 20 ms after treatment. Thus, even if there was a causal relationship between plasma potassium and QTc dispersion, it would not appear to fully explain our results. There are 3 additional reasons for this contention. First, we failed to find any correlation between plasma potassium and QT dispersion. Second, QTc max 26 would be expected to be more sensitive to changes in plasma potassium, but in our study this was not significantly altered with salt and fludrocortisone. Third, changes in plasma potassium should not cause the LV stiffness/diastolic dysfunction that we saw on echocardiographic examination. Nonetheless, the role of potassium on QT dispersion during salt loading in hypertensive subjects deserves to be explored further, since some degree of potassium loss occurs whenever salt intake is increased.
Conclusions
Salt with fludrocortisone increased QT dispersion and impaired LV diastolic relaxation in hypertensive patients with high ARR. Therefore, in this subpopulation of hypertensive patients, salt could cause important cardiac target-organ damage. These findings provide a potentially novel mechanism whereby an increase in salt intake might amplify the risk of sudden cardiac death in high-risk hypertensive subjects. Our data should, however, be treated as pilot and cannot be extrapolated to the wider hypertensive population. Nevertheless, the role of salt in QT dispersion and LV diastolic function merits further study.
